Stevenage, UK based Antikor Biopharma is developing ADCs using 'OptiLinked' smaller antibody fragments

blonca9
Jul 17, 2024
1 min read

CEO Mahendra Deonarian describes the potential advantages of this approach over traditional ADCs and talks about the company's lead program that targets CMET.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Stevenage, UK based Antikor Biopharma is developing ADCs using 'OptiLinked' smaller antibody fragments

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight